| Trial | Amiodarone patients | Placebo patients | Daily amiodarone maintenance dose (mg) | Follow-up (months) | Mortality benefit | Cancer in placebo group | Cancer in amiodarone group |
| Hamer et al. (1989)12 | 19 | 15 | 200 | 23 | No | 0 | 2* (10.5%) |
| Ceremuzynski et al. (1992)10 | 305 | 308 | 400 | 12 | Yes | 0 | 1—stomach cancer (0.3%) |
| Cairns et al. (1997)13 | 606 | 596 | 200 | 21 | Yes | 0 | 1—metastatic ovarian cancer (0.2%) |
| Julian et al. (1997)5 | 743 | 743 | 200 | 21 | No | 4 (0.5%) | 6* (0.8%) |
| Elizari et al. (2000)14 | 542 | 531 | high & low | 6 | No | 0 | 4*—determined to be present prior to enrollment |
| Roy et al. (2000)15 | 201 | 202 (sotalol or propafenone) | 200 | short duration | NA | ?*,+ | ?*,+ |